Certain breast cancers have a trait that could be attacked by new therapies

More than 100 women per day die from breast cancer in the United States. The odds of developing breast cancer increase for women taking hormone replacement therapy to avoid the effects of menopause. New research by University of Missouri scientist Salman Hyder may lead to treatments for breast cancers associated with taking these synthetic hormones. Hyder, along with an international team, found that hormone-therapy-related breast cancer cells have a physical feature that could be attacked by cancer therapies.

"We identified a specific cell membrane protein that blocks cell death in breast cancer cells and allows these cells to grow in response to ," said Hyder. "Others have observed an over-abundance of these proteins in a population of which may explain increased risk of in women who consume hormone replacement therapy. Therapies could be developed that would block the activity of these cell membrane proteins, which would make cancer cells more likely to die. The membrane protein is known as PGRMC1."

The proteins identified by Hyder and his colleagues were affected by progestin, one of the hormones given to women to stave off the effects of menopause. Progestin is a synthetic chemical which mimics the . In hormone replacement therapy, doctors prescribe progestin along with synthetic replicas of the hormone, estrogen.

"Every progestin type that we have tested has negative effects," said Hyder. "A growing body of evidence suggests women should be wary before taking progestin. However, if women take only synthetic estrogens, such as estradiol, it leads to a higher risk of uterine cancer. Hence, the two must be taken together, but even then they seem to still increase cancer risks in post-menopausal women."

The study "Overexpression of progesterone receptor membrane component 1: possible mechanism for increased with norethisterone in hormone therapy" was published in the journal Menopause.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.